In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
暂无分享,去创建一个
H. Ueno | K. Tatsugami | S. Naito | K. Takayama | M. Harada | M. Eto | N. Tokuda | H. Ichikura
[1] K. Tatsugami,et al. Anti‐tumour activity of heat‐shock protein 60‐recognizing CD4+ T cells against syngeneic murine renal cell carcinoma , 2005, BJU international.
[2] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[3] A. Davidoff,et al. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. , 2002, Cancer research.
[4] T. Sayers,et al. Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin1 , 2002, The Journal of Immunology.
[5] M. Smyth,et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. , 2001, Cellular immunology.
[6] R. D'Amato,et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[7] K. Tamada,et al. Antitumor activity of interleukin-12 against murine bladder cancer. , 2000, The Journal of urology.
[8] K. Inoue,et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. , 2000, Cancer research.
[9] Nina Bhardwaj,et al. Consequences of cell death: exposure to necrotic tumor cells , 2000 .
[10] Stefania Gallucci,et al. Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.
[11] F. Marincola,et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. , 1998, Journal of the National Cancer Institute.
[12] K.,et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[13] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[14] Mihaela Skobe,et al. Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.
[15] W. Cavenee,et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[16] Y. Kanegae,et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[17] A. Takeshita,et al. Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[18] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[19] N. Ferrara,et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.
[20] 原野 正彦. Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice , 2006 .
[21] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.